News for Celcuity Inc. (CELC)

MINNEAPOLIS, May 21, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. ( CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for onc

Celcuity Inc. (CELC) to present at TD Cowen and Jefferies Investor Conferences. CEO Brian Sullivan to lead discussions on May 28 and June 5, 2025. Li

Operator: Good afternoon, ladies and gentlemen, and welcome to the Celcuity First Quarter 2025 Financial Results Webcast Conference Call. At this time all lines are in listen-only mode.

Celcuity (CELC), a cutting-edge biotechnology company, has had its stock position reiterated as a "Buy" by Needham, one of the prominent firms in financial anal

Net Loss: $37 million or $0.86 per share for Q1 2025, compared to $21.6 million or $0.6 per share for Q1 2024.Non-GAAP Adjusted Net Loss: $34.7 million or $0.8

May 14, 2025 / 08:30PM GMTOperator Good afternoon, ladies and gentlemen, and welcome to the Celcuity first-quarter 2025 financial results webcast conference cal

The following slide deck was published by Celcuity Inc.

Celcuity Inc. reveals promising updates on cancer trials with major topline results expected in 2025.

Celcuity Inc. (NASDAQ:CELC) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ETCompany ParticipantsApoorva Chaloori - ICR HealthcareBrian Sullivan -...

MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. ( CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for onc

U.S. stock futures were higher this morning, with the Dow futures gaining around 300 points on Tuesday. Shares of Northrop Grumman Corporation NOC shares fell ...

**media[595708]**

While Donald Trump spared pharma companies from his tariff announcement last week, he revealed yesterday plans to announce tariffs on the industry soon.

U.S. stock futures were higher this morning, with the Dow futures gaining more than 900 points on Tuesday. Shares of The Greenbrier Companies, Inc. GBX fell sh...

The following slide deck was published by Celcuity Inc.

Discover Celcuity's Q4 2024 insights: gedatolisib's promising trials for breast cancer, $2B market potential, and key 2025 milestones.

Celcuity Inc. (NASDAQ:CELC) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ETCompany ParticipantsApoorva Chaloori - ICR Healthcare, Investor...

**media[574560]**

PR NewswireVANCOUVER, BC, Feb. 27, 2025 USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 27, 2025 /PRNewswire/ -- US